文献速递妇科产科

BEHOLD 3期临床开发项目:mocertatug rezetecan 用于卵巢癌和子宫内膜癌

BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2026-11-11

Mocertatug rezetecan(Mo-Rez)是靶向B7-H4的抗体药物偶联物,1期BEHOLD-1研究中在铂耐药卵巢癌客观缓解率为62%、在复发/晚期子宫内膜癌为67%。BEHOLD 3期项目包含五项随机研究,计划入组约3070例患者,覆盖卵巢癌和子宫内膜癌多个治疗场景。

要点

  • Mo-Rez为靶向B7-H4的抗体药物偶联物,载荷为拓扑异构酶I抑制剂rezetecan。
  • 1期BEHOLD-1中铂耐药卵巢癌客观缓解率62%,复发/晚期子宫内膜癌67%。
  • 3期BEHOLD项目含五项随机研究,计划入组约3070例患者。

核心结论

  • BEHOLD项目是全面的3期临床开发项目,旨在评估Mo-Rez在多种卵巢癌和子宫内膜癌场景中的疗效与安全性,并进一步明确B7-H4作为妇科恶性肿瘤治疗靶点的临床相关性。

研究设计与样本

  • 全球BEHOLD 3期临床项目由五项随机研究组成,计划入组约3070例患者,覆盖卵巢癌与子宫内膜癌治疗场景。
  • 卵巢癌研究包括铂耐药病(BEHOLD-Ovarian01,NCT07286266)、铂敏感病(BEHOLD-Ovarian02,NCT076684612)及非同源重组缺陷病一线维持(BEHOLD-Ovarian03,NCT07694427)。
  • 子宫内膜癌研究包括既往治疗过的晚期/复发病(BEHOLD-Endometrial01,NCT07286331)及错配修复 proficient 病一线维持(BEHOLD-Endometrial02,NCT07684599)。

主要发现

  • 1期BEHOLD-1研究(NCT06431594)中,Mo-Rez在铂耐药卵巢癌的客观缓解率为62%,在复发/晚期子宫内膜癌为67%。
  • 主要终点包括无进展生存期和总生存期,具体取决于研究设计。
  • 次要与探索性终点包括安全性、药代动力学、生物标志物、免疫原性与生活质量评估。
  • BEHOLD项目评估三种治疗策略:以B7-H4导向的抗体药物偶联物替代传统化疗、与贝伐珠单抗或免疫检查点抑制剂联合、以及Mo-Rez用作维持治疗。
  • 各研究收集肿瘤组织,可前瞻性评估B7-H4表达及其他生物标志物作为临床获益预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mocertatug rezetecan (Mo-Rez; GSK5733584) is a B7-H4-targeting antibody-drug conjugate comprising a humanized anti-B7-H4 monoclonal antibody linked to the topoisomerase I inhibitor rezetecan. In the Phase 1 BEHOLD-1 study (NCT06431594), Mo-Rez demonstrated encouraging antitumor activity in platinum-resistant ovarian cancer (objective response rate [ORR], 62%) and recurrent/advanced endometrial cancer (ORR, 67%), supporting further clinical evaluation in Phase 3 studies. The global BEHOLD Phase 3 clinical program consists of five randomized studies evaluating Mo-Rez across ovarian and endometrial cancer treatment settings, with approximately 3,070 patients planned for enrollment. The ovarian cancer studies evaluate platinum-resistant disease (BEHOLD-Ovarian01, NCT07286266), platinum-sensitive disease (BEHOLD-Ovarian02, NCT076684612), and first-line maintenance for non-homologous recombination deficient disease (BEHOLD-Ovarian03, NCT07694427). The endometrial cancer studies evaluate previously treated advanced/recurrent disease (BEHOLD-Endometrial01, NCT07286331) and first-line maintenance for mismatch repair proficient disease (BEHOLD-Endometrial02, NCT07684599). Primary endpoints include progression-free survival (PFS) and overall survival (OS), depending on study design. Secondary and exploratory endpoints include safety, pharmacokinetics, biomarkers, immunogenicity, and quality-of-life assessments. Collectively, the BEHOLD program evaluates three therapeutic strategies: replacement of conventional chemotherapy with a B7-H4-directed ADC, combination approaches with bevacizumab or immune checkpoint inhibitors, and use of Mo-Rez as maintenance therapy. Tumor tissue collection across studies enables prospective evaluation of B7-H4 expression and other biomarkers as predictors of clinical benefit. The BEHOLD program represents a comprehensive Phase 3 clinical development effort designed to evaluate the efficacy and safety of Mo-Rez across multiple ovarian and endometrial cancer settings and to further characterize the clinical relevance of B7-H4 as a therapeutic target in gynecologic malignancies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hurteau J, Grayeski M, Dixon J, et al. BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer. Gynecol Oncol. 2026. PMID: 43013925. doi:10.1016/j.ygyno.2026.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。